ArticleBlood advances2020
High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential.
Article in Blood advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 94 citations in OpenAlex.
- Trial
- HIV is associated with an increased risk of age-related clonal hematopoiesis among older adults.Nature medicine · 2021Trial
- Leveraging Dietary Interventions to Benefit Patients with Hematologic Malignancies and Clonal Hematopoiesis.Nutrients · 2026Review
- Clonal hematopoiesis and thrombosis risk-what are research and clinical gaps?Research and practice in thrombosis and haemostasis · 2026Review
- Clonal Hematopoiesis in Cardiovascular Risk: Focus on Inflammatory Mechanisms.Journal of clinical medicine · 2026Review
- The Link between Modifiable Risk Factors and Myeloid Disorders-From Plate to Pathogenesis.Blood cancer discovery · 2026Review
- Clonal Hematopoiesis of Indeterminate Potential and Cardiometabolic Disease: Challenges, Controversies and Future Perspectives.International journal of molecular sciences · 2025Review
- Clonal Hematopoiesis and Cardiovascular Events in Patients with ESKD on Hemodialysis: Results from the VIVALDI Study.Clinical journal of the American Society of Nephrology : CJASN · 2025Article
- Target practice: Opportunities for therapeutic intervention in CHIP and CCUS.Blood reviews · 2025Review
- Causal relevance of clonal haematopoiesis with cardiac disease and adverse remodelling: a Mendelian randomisation study.Open heart · 2025Article
- Clonal hematopoiesis of indeterminate potential: contribution to disease and promising interventions.Molecular and cellular biochemistry · 2025Review
- Clonal Hematopoiesis and Thrombosis.American journal of hematology · 2025Review
- Clonal hematopoiesis is associated with distinct rheumatoid arthritis phenotypes.Science advances · 2025Article
- Clonal hematopoiesis in patients with cancer and its association with risk of thrombosis and prognosis of disease.Research and practice in thrombosis and haemostasis · 2025Article
- Inflammatory reprogramming of the solid tumor microenvironment by infiltrating clonal hematopoiesis is associated with adverse outcomes.Cell reports. Medicine · 2025Article
- Biomarkers in clonal haematopoiesis of indeterminate potential (CHIP) linking cardiovascular diseases, myeloid neoplasms and inflammation.Annals of hematology · 2025Review
- Association of clonal haematopoiesis with recurrent venous thromboembolism: A case-control study.British journal of haematology · 2025Article
- Clonal hematopoiesis at the crossroads of Inflammaging and cardiovascular disease: Mechanistic insights and translational horizons.Clinical hematology international · 2025Review
- Impact of immunological aging on T cell-mediated therapies in older adults with multiple myeloma and lymphoma.Journal for immunotherapy of cancer · 2024Review
- Somatic mutations in aging and disease.GeroScience · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 2 countries.
Funding
Abstract
Clonal hematopoiesis of indeterminate potential (CHIP) is predictive of hematological cancers and cardiovascular diseases, but the etiology of CHIP initiation and clonal expansion is unknown. Several lines of evidence suggest that proinflammatory cytokines may favor mutated hematopoietic stem cell expansion. To investigate the potential link between inflammation and CHIP, we performed targeted deep sequencing of 11 genes previously implicated in CHIP in 1887 subjects aged >70 years from the Montreal Heart Institute Biobank, of which 1359 had prior coronary artery disease (CAD), and 528 controls did not. We assessed association of CHIP with log transformed high-sensitivity C-reactive protein (hs-CRP), a validated biomarker of inflammation. CHIP was identified in 427 of the 1887 subjects (22.6%). CHIP mutations were more frequently identified in DNMT3A (11.6%) and TET2 (6.1%), with a higher proportion of TET2 mutations occurring in controls than in patients with CAD (9.0% vs 4.9%, P < .001). CHIP carriers had 21% higher hs-CRP levels compared with their noncarrier counterparts (eβ = 1.21, 95% confidence interval [CI]: 1.08 to 1.36; P = .001). A similar effect was observed in the subgroup of patients with known CAD (eβ = 1.22, 95% CI: 1.06 to 1.41; P = .005). These findings confirm the association between inflammation and CHIP. This association may open investigational avenues aimed at documenting mechanisms linking inflammation to clonal progression and ultimately supports prevention interventions to attenuate CHIP's impact on cardiovascular disease and cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.